Citation Impact
Citing Papers
Programmed Cell Death Ligand 1 (PD-L1) Signaling Regulates Macrophage Proliferation and Activation
2018
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
2018
PD-1 + regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer
2019 StandoutNobel
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
Breast cancer
2019 Standout
Basal cell carcinomas: attack of the hedgehog
2008 Standout
Polymorphisms in DNA Double-Strand Break Repair Genes and Skin Cancer Risk
2004
The history and advances in cancer immunotherapy: understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications
2020 Standout
Cancer treatment and survivorship statistics, 2022
2022 Standout
Fas-based d1OS-mediated cytotoxicity requires macromolecular synthesis for effector cell activation but not for target cell death
1994
A role for CD95 ligand in preventing graft rejection
1995 StandoutNature
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
Adverse effects of immune-checkpoint inhibitors: epidemiology, management and surveillance
2019 Standout
Top 10 Challenges in Cancer Immunotherapy
2020
Biomarkers of response to PD-1/PD-L1 inhibition
2017
Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications
1994 Standout
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Predictive factors for hyperprogressive disease during nivolumab as anti-PD1 treatment in patients with advanced gastric cancer
2019
Effects of alloimmune injury on contraction and relaxation in cultured myocytes and intact cardiac allografts
1994
ATM and related protein kinases: safeguarding genome integrity
2003 Standout
Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment—A Review From the Melanoma Perspective and Beyond
2018
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
2017 Standout
First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, single-arm, phase 2 study
2017 Standout
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
2017
Delivery technologies for cancer immunotherapy
2019 Standout
Lung cancer: current therapies and new targeted treatments
2016 Standout
Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials
2017
Intraepidermal lymphocytes in psoriatic lesions are activated GMP‐17(TIA‐1)+CD8+CD3+ CTLs as determined by phenotypic analysis
1998 StandoutNobel
European Association of Urology Guidelines on Muscle-invasive and Metastatic Bladder Cancer: Summary of the 2020 Guidelines
2020 Standout
Telomere fusion to chromosome breaks reduces oncogenic translocations and tumour formation
2005 StandoutNobel
Further Advances in Cancer Immunotherapy: Going Beyond Checkpoint Blockade
2018
Caspase Functions in Cell Death and Disease
2013 Standout
Drug development in the era of precision medicine
2017
Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract
2017
Recombinational DNA repair and human disease
2002
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Management of Chronic Kidney Disease Patients in the Intensive Care Unit: Mixing Acute and Chronic Illness
2017 Standout
The versatility of macrophages
1992
Macrophages as regulators of tumour immunity and immunotherapy
2019 Standout
PROTAC targeted protein degraders: the past is prologue
2022 Standout
Association of a Common Variant of the CASP8 Gene With Reduced Risk of Breast Cancer
2004
Perforin: structure and function
1995
The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review
2017
Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms
2013 Standout
Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis
2017
Immune checkpoint inhibitors: recent progress and potential biomarkers
2018 Standout
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
2018 Standout
The PI3K Pathway in Human Disease
2017 Standout
Mechanisms of BCG immunotherapy and its outlook for bladder cancer
2018
Unwrapping the genomic characteristics of urothelial bladder cancer and successes with immune checkpoint blockade therapy
2018
Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer
2016
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
2009 Standout
Adenovirus-mediated gene transfer of the β2-adrenergic receptor to donor hearts enhances cardiac function
1999 StandoutNobel
Contribution of Organofluorine Compounds to Pharmaceuticals
2020 Standout
Mapping the Efficiency and Physicochemical Trajectories of Successful Optimizations
2018
Mutation of the mouse klotho gene leads to a syndrome resembling ageing.
1997 Standout
Avelumab, an Anti–Programmed Death-Ligand 1 Antibody, In Patients With Refractory Metastatic Urothelial Carcinoma: Results From a Multicenter, Phase Ib Study
2017
Efficacy and Safety of Durvalumab in Locally Advanced or Metastatic Urothelial Carcinoma
2017
Bladder Cancer
2020 Standout
Breast Cancer Treatment
2019 Standout
Small Cell Lung Cancer: Will Recent Progress Lead to Improved Outcomes?
2015
The role of DNA breaks in genomic instability and tumorigenesis
2003
Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations
2018
Tubulointerstitial Changes as a Major Determinant in the Progression of Renal Damage
1992 Standout
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
A minimally designed PD-L1-targeted nanocomposite for positive feedback-based multimodal cancer therapy
2022
Fluorine‐Containing Drugs Approved by the FDA in 2018
2019
Mechanisms of Renal Fibrosis
2017 Standout
Cancer immunotherapy using checkpoint blockade
2018 StandoutScience
Photothermal Nanomaterials: A Powerful Light-to-Heat Converter
2023 Standout
The Cytolytic P 2Z Receptor for Extracellular ATP Identified as a P 2X Receptor (P2X 7 )
1996 StandoutScience
Safety profile of avelumab in patients with advanced solid tumors: A pooled analysis of data from the phase 1 JAVELIN solid tumor and phase 2 JAVELIN Merkel 200 clinical trials
2018
Works of Saeed Rafii being referenced
Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers
2017
A potential role for the XRCC2 R188H polymorphic site in DNA-damage repair and breast cancer
2002
How Lymphocytes Kill
1990
Safety and efficacy of durvalumab (MEDI4736), a PD-L1 antibody, in urothelial bladder cancer.
2016
Safety and antitumor activity of the PARP inhibitor BMN673 in a phase 1 trial recruiting metastatic small-cell lung cancer (SCLC) and germline BRCA-mutation carrier cancer patients.
2014
Safety and Efficacy of Durvalumab (MEDI4736), an Anti–Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor, in Patients With Advanced Urothelial Bladder Cancer
2016